The sale is part of a pre-arranged 10b5-1 plan and is small relative to market cap, so it does not signal a change in insider sentiment. Monitor for any acceleration of insider selling beyond the plan's disclosed schedule.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $99.55entry
- T+1 · 13d ago +1.87%α +0.22% · $101.41
- T+5 · 7d ago +9.99%α +10.58% · $109.50
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Lawrence Klein filed a Form 144 notice of intent to sell 25,000 shares of Oruka Therapeutics common stock, with an estimated aggregate market value of approximately $2.42 million based on the filing price. The sale is planned for November 2, 2026, and the shares were acquired through the exercise of stock options. Klein has a history of recent sales under a 10b5-1 plan, including 75,000 shares sold on September 1, 2026, and 25,000 shares sold on October 1, 2026, totaling over $9 million in recent dispositions.
Key Facts
- Director Lawrence Otto Klein filed Form 144 to sell 25,000 shares of Oruka Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is $2,421,750.
- Shares were acquired via exercise of stock options on November 2, 2026.
- Klein has sold 100,000 shares in the prior two months under a 10b5-1 plan (75,000 on Sep 1, 2026 and 25,000 on Oct 1, 2026).
- The 25,000 shares represent approximately 0.04% of the company's $6.4B market cap.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 25,000 shares valued at ~$2.42M, representing ~0.04% of market cap.
Risk Factors
- Form 144 is only an intent to sell; the actual sale may not occur.
- Insider has sold over $9M in shares in the past two months under the same 10b5-1 plan, which could indicate ongoing portfolio diversification rather than a negative view.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010585 |
| Document: 0001950047-26-010585-index.html | 0001950047-26-010585 |
| Document: 0001950047-26-010585.txt | 0001950047-26-010585 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Viewing Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers